436 related articles for article (PubMed ID: 33229321)
1. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
Bao LW; Zhou YY; Zeng FY
Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
Alayoubi AM; Khawaji ZY; Mohammed MA; Mercier FE
Ann Hematol; 2024 Jun; 103(6):1805-1817. PubMed ID: 37736806
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
Laurent M; Geoffroy M; Pavani G; Guiraud S
Cells; 2024 May; 13(10):. PubMed ID: 38786024
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
6. [Research progress of CRISPR-Cas9 system for gene therapy].
Zhan C; Xia X
Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
[TBL] [Abstract][Full Text] [Related]
7. CRISPR gene therapy shows promise against blood diseases.
Ledford H
Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
[No Abstract] [Full Text] [Related]
8. CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.
Gabr H; El Ghamrawy MK; Almaeen AH; Abdelhafiz AS; Hassan AOS; El Sissy MH
Stem Cell Res Ther; 2020 Sep; 11(1):390. PubMed ID: 32912325
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
10. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
11. CRISPR in personalized medicine: Industry perspectives in gene editing.
Hong A
Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
13. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
15. Advances in therapeutic CRISPR/Cas9 genome editing.
Savić N; Schwank G
Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
[TBL] [Abstract][Full Text] [Related]
16. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
17. In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia.
Lee JH; Han JP
Mol Diagn Ther; 2024 May; 28(3):239-248. PubMed ID: 38538969
[TBL] [Abstract][Full Text] [Related]
18. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Mehta J
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
